---
title: "Autolus Therapeutics Q2 2026 earnings preview"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295425283.md"
description: "Autolus Therapeutics (AUTL) will report Q2 2026 earnings on August 11th. Consensus estimates project an EPS of -$0.19 and revenue of $40.15M, reflecting a 92.1% year-over-year increase. Historically, the company has beaten EPS estimates 50% of the time and revenue estimates 25% of the time over the past year."
datetime: "2026-08-10T15:13:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295425283.md)
  - [en](https://longbridge.com/en/news/295425283.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295425283.md)
generator: "portal-rs"
---

# Autolus Therapeutics Q2 2026 earnings preview

Autolus Therapeutics (AUTL) is scheduled to announce Q2 earnings results on Tuesday, August 11th, before market open. The consensus EPS Estimate is -$0.19 (-5.6% Y/Y) and the consensus Revenue Estimate is $40.15M (+92.1% Y/Y). Over the last 1 year, AUTL has beaten EPS estimates 50% of the time and has beaten revenue estimates 25% of the time. Over ...

### Related Stocks

- [AUTL.US](https://longbridge.com/en/quote/AUTL.US.md)

## Related News & Research

- [Autolus says FDA grants RMAT designation for obe-cel in lupus, lupus nephritis](https://longbridge.com/en/news/298445726.md)
- [Autolus Therapeutics (NASDAQ:AUTL) Releases Earnings Results, Beats Estimates By $0.06 EPS](https://longbridge.com/en/news/295550852.md)
- [Ameren forecasts 2026 EPS of $5.25-$5.45](https://longbridge.com/en/news/298331518.md)
- [Camden Property Trust guides 2026 core FFO per share at $6.68-$6.82](https://longbridge.com/en/news/298370141.md)
- [Chime raises 2026 revenue outlook to $2.76-$2.77 billion](https://longbridge.com/en/news/298359842.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**